CN101909643A - 干酪乳杆菌菌株用于制备抑制肥大细胞活化之组合物的用途 - Google Patents

干酪乳杆菌菌株用于制备抑制肥大细胞活化之组合物的用途 Download PDF

Info

Publication number
CN101909643A
CN101909643A CN200880124467XA CN200880124467A CN101909643A CN 101909643 A CN101909643 A CN 101909643A CN 200880124467X A CN200880124467X A CN 200880124467XA CN 200880124467 A CN200880124467 A CN 200880124467A CN 101909643 A CN101909643 A CN 101909643A
Authority
CN
China
Prior art keywords
bacteria
cells
composition
mast cells
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880124467XA
Other languages
English (en)
Chinese (zh)
Inventor
塞西尔·希弗-曼尼维
马克·达埃龙
桑德里纳·萨姆森
拉斐尔莱·布尔代-西卡尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gervais Danone SA
Institut Pasteur
Original Assignee
Gervais Danone SA
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gervais Danone SA, Institut Pasteur filed Critical Gervais Danone SA
Publication of CN101909643A publication Critical patent/CN101909643A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Nutrition Science (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
CN200880124467XA 2007-11-30 2008-12-01 干酪乳杆菌菌株用于制备抑制肥大细胞活化之组合物的用途 Pending CN101909643A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07291431.0 2007-11-30
EP07291431A EP2065048A1 (en) 2007-11-30 2007-11-30 Use of a L. casei strain, for the preparation of a composition for inhibiting mast cell activation
PCT/IB2008/003690 WO2009068997A1 (en) 2007-11-30 2008-12-01 Use of a l. casei strain, for the preparation of a composition for inhibiting mast cell activation

Publications (1)

Publication Number Publication Date
CN101909643A true CN101909643A (zh) 2010-12-08

Family

ID=39323735

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880124467XA Pending CN101909643A (zh) 2007-11-30 2008-12-01 干酪乳杆菌菌株用于制备抑制肥大细胞活化之组合物的用途

Country Status (7)

Country Link
US (1) US20100284973A1 (enExample)
EP (2) EP2065048A1 (enExample)
JP (1) JP2011505349A (enExample)
CN (1) CN101909643A (enExample)
AR (1) AR069520A1 (enExample)
RU (1) RU2010126596A (enExample)
WO (1) WO2009068997A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103097513A (zh) * 2010-03-12 2013-05-08 热尔韦·达诺尼公司 用于乳糜泻的乳酸菌
CN103257237A (zh) * 2013-05-09 2013-08-21 中国农业大学 一种食品中过敏原的体外检测方法
CN109266584A (zh) * 2018-10-18 2019-01-25 扬州大学 一株具有肥大细胞活性调节作用的纤毛型鼠李糖乳杆菌及其用途
CN109312297A (zh) * 2015-12-11 2019-02-05 营养健康有限公司 用于治疗肥胖症和相关代谢病的干酪乳杆菌
CN111587118A (zh) * 2018-01-12 2020-08-25 Gi 医诺微新 包含益生菌和具有与IgE结合能力的多肽的组合物及其用途

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2924307B1 (fr) * 2007-12-04 2010-08-27 Gervais Danone Sa Utilisation de l. casei ssp. paracasei comme antifongique
WO2010013143A2 (en) * 2008-08-01 2010-02-04 Institut Pasteur Methods for inhibiting mast cell activation and treating mast cell-dependent inflammatory diseases and disorders using lactobacillus
KR101275227B1 (ko) * 2010-10-13 2013-06-18 광주과학기술원 중증근무력증 예방, 개선 또는 치료용 조성물
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
EP3193901B1 (en) 2014-12-23 2018-04-04 4D Pharma Research Limited Pirin polypeptide and immune modulation
ES2658310T3 (es) 2014-12-23 2018-03-09 4D Pharma Research Limited Una cepa de bacteroides thetaiotaomicron y su uso en la reducción de la inflamación
MA55434B1 (fr) * 2015-06-15 2022-02-28 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
PT3307288T (pt) 2015-06-15 2019-10-17 4D Pharma Res Ltd Composições compreendendo estirpes bacterianas
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
TWI759266B (zh) 2015-06-15 2022-04-01 英商4D製藥研究有限公司 包含細菌菌株之組合物之用途
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
MA45287A (fr) 2015-11-20 2018-08-22 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
PT3313423T (pt) 2016-03-04 2019-07-10 4D Pharma Plc Composições que compreendem a estirpe blautia bacteriana para tratar a hipersensibilidade visceral
TWI802545B (zh) 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
RS61872B1 (sr) 2017-05-22 2021-06-30 4D Pharma Res Ltd Kompozicije koje sadrže bakterijske sojeve
WO2018215782A1 (en) 2017-05-24 2018-11-29 4D Pharma Research Limited Compositions comprising bacterial strain
RS63393B1 (sr) 2017-06-14 2022-08-31 4D Pharma Res Ltd Kompozicije koje sadrže bakterijske sojeve
JP6840272B2 (ja) 2017-06-14 2021-03-10 フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ 細菌株を含む組成物
EP3638271B1 (en) 2017-06-14 2020-10-14 4D Pharma Research Limited Compositions comprising bacterial strains

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1099271A (zh) * 1993-08-23 1995-03-01 王世荣 生态口服液
CN1114354A (zh) * 1994-06-23 1996-01-03 江苏省纺织(集团)总公司实业开发分公司 双歧杆菌在含中药培养基中进行有氧发酵的方法
CN1380902A (zh) * 2000-05-17 2002-11-20 株式会社百尼尔 治疗或预防肥胖症和糖尿病的微生物及含有所述微生物的药物组合物
CN1493305A (zh) * 2002-10-29 2004-05-05 西安大鹏生物科技股份有限公司 一种肠道微生态调节剂
CN1556853A (zh) * 2001-07-26 2004-12-22 益生菌干酪乳杆菌菌株
CN1561387A (zh) * 2001-07-26 2005-01-05 营养健康有限公司 益生菌双歧杆菌菌株
CN1696281A (zh) * 2004-05-10 2005-11-16 景岳生物科技股份有限公司 新的微生物株类干酪乳杆菌gm－080及其治疗过敏相关疾病的用途
CN1795027A (zh) * 2002-12-05 2006-06-28 达尼斯科（法国）公司 包括乳酸杆菌或双歧杆菌组合物及其用途
CN1957953A (zh) * 2005-10-14 2007-05-09 德阳创新生物工程有限公司 一种具免疫调节功能的多菌组合物及其制备方法与用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2617758B2 (ja) * 1988-03-25 1997-06-04 株式会社ヤクルト本社 抗体産生増強型免疫賦活剤
AUPQ415899A0 (en) * 1999-11-19 1999-12-16 Vasse Research Institute Pty Ltd Compositions for and methods of treatment of allergic diseases
NZ546664A (en) * 2003-10-24 2009-04-30 Nutricia Nv Synbiotic composition for infants
US7351572B2 (en) * 2004-10-15 2008-04-01 Genmont Biotech Inc. Microorganism strain GM-090 of Lactobacillus fermentum and its use for stimulating IFN-γ secretion and/or treating allergy
EP1683425A1 (en) * 2005-01-21 2006-07-26 Compagnie Gervais Danone Use of a fermented milk containing L. Casei for the manufacture of a composition for the prevention or treatment of a delayed-type hypersensitivity reaction
WO2007035057A1 (en) * 2005-09-23 2007-03-29 Gwangju Institute Of Science And Technology Composition for preventing or treating artritis comprising lactic acid bacteria and collangen as active ingredients
JP2007117031A (ja) * 2005-10-31 2007-05-17 Nakagaki Gijutsushi Jimusho:Kk インターフェロンガンマ発現誘導作用を有する発酵乳、及び発酵乳製造用種菌

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1099271A (zh) * 1993-08-23 1995-03-01 王世荣 生态口服液
CN1114354A (zh) * 1994-06-23 1996-01-03 江苏省纺织(集团)总公司实业开发分公司 双歧杆菌在含中药培养基中进行有氧发酵的方法
CN1380902A (zh) * 2000-05-17 2002-11-20 株式会社百尼尔 治疗或预防肥胖症和糖尿病的微生物及含有所述微生物的药物组合物
CN1556853A (zh) * 2001-07-26 2004-12-22 益生菌干酪乳杆菌菌株
CN1561387A (zh) * 2001-07-26 2005-01-05 营养健康有限公司 益生菌双歧杆菌菌株
CN1493305A (zh) * 2002-10-29 2004-05-05 西安大鹏生物科技股份有限公司 一种肠道微生态调节剂
CN1795027A (zh) * 2002-12-05 2006-06-28 达尼斯科（法国）公司 包括乳酸杆菌或双歧杆菌组合物及其用途
CN1696281A (zh) * 2004-05-10 2005-11-16 景岳生物科技股份有限公司 新的微生物株类干酪乳杆菌gm－080及其治疗过敏相关疾病的用途
CN1957953A (zh) * 2005-10-14 2007-05-09 德阳创新生物工程有限公司 一种具免疫调节功能的多菌组合物及其制备方法与用途

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103097513A (zh) * 2010-03-12 2013-05-08 热尔韦·达诺尼公司 用于乳糜泻的乳酸菌
CN103097513B (zh) * 2010-03-12 2018-01-30 热尔韦·达诺尼公司 用于乳糜泻的乳酸菌
CN103257237A (zh) * 2013-05-09 2013-08-21 中国农业大学 一种食品中过敏原的体外检测方法
CN103257237B (zh) * 2013-05-09 2015-05-20 中国农业大学 一种食品中过敏原的体外检测方法
CN109312297A (zh) * 2015-12-11 2019-02-05 营养健康有限公司 用于治疗肥胖症和相关代谢病的干酪乳杆菌
CN109312297B (zh) * 2015-12-11 2022-09-23 精密生物集团有限公司 用于治疗肥胖症和相关代谢病的干酪乳杆菌
CN111587118A (zh) * 2018-01-12 2020-08-25 Gi 医诺微新 包含益生菌和具有与IgE结合能力的多肽的组合物及其用途
CN111587118B (zh) * 2018-01-12 2023-11-21 Gi 医诺微新 包含益生菌和具有与IgE结合能力的多肽的组合物及其用途
CN109266584A (zh) * 2018-10-18 2019-01-25 扬州大学 一株具有肥大细胞活性调节作用的纤毛型鼠李糖乳杆菌及其用途
CN109266584B (zh) * 2018-10-18 2020-09-08 扬州大学 一株具有肥大细胞活性调节作用的纤毛型鼠李糖乳杆菌及其用途

Also Published As

Publication number Publication date
AR069520A1 (es) 2010-01-27
WO2009068997A1 (en) 2009-06-04
EP2065048A1 (en) 2009-06-03
EP2224936A1 (en) 2010-09-08
US20100284973A1 (en) 2010-11-11
JP2011505349A (ja) 2011-02-24
RU2010126596A (ru) 2012-01-10

Similar Documents

Publication Publication Date Title
CN101909643A (zh) 干酪乳杆菌菌株用于制备抑制肥大细胞活化之组合物的用途
Alam et al. Role of gut microbiota in intestinal wound healing and barrier function
Magistrelli et al. Probiotics may have beneficial effects in Parkinson's disease: in vitro evidence
Sakai et al. Lactobacillus gasseri SBT2055 induces TGF-β expression in dendritic cells and activates TLR2 signal to produce IgA in the small intestine
US20210315947A1 (en) Microbial consortium and uses thereof
JP7250059B2 (ja) 新規のビフィドバクテリウムビフィダム菌株及び菌株由来多糖体
Roselli et al. Beneficial effects of a selected probiotic mixture administered to high fat-fed mice before and after the development of obesity
US20120087902A1 (en) Therapeutic Use Of Probiotics
KR102225939B1 (ko) 신규한 Bacteroides vulgatus 균주 및 이를 유효 성분으로 하는 면역 및 대사성 질환 예방 또는 치료용 조성물
Huang et al. Gut REG3γ-associated Lactobacillus induces anti-inflammatory macrophages to maintain adipose tissue homeostasis
Perrin et al. Comparison of two oral probiotic preparations in a randomized crossover trial highlights a potentially beneficial effect of Lactobacillus paracasei NCC2461 in patients with allergic rhinitis
Liu et al. Probiotics alleviate inflammatory bowel disease in mice by regulating intestinal microorganisms-bile acid-NLRP3 inflammasome pathway
Ogita et al. Streptococcus thermophilus ST28 ameliorates colitis in mice partially by suppression of inflammatory Th17 cells
US20100028263A1 (en) Methods for inhibiting mast cell activation and treating mast cell-dependent inflammatory diseases and disorders using lactobacillus
JP2021526526A (ja) 細菌株を含む組成物
Lockyer et al. The role of probiotics on the roadmap to a healthy microbiota: A symposium report
Janakiraman Regulation of spontaneous CNS autoimmunity by dietary salt
Lin The Role of A. muciniphila in Multiple Sclerosis
Ninnemann The significance of microbiota-immune system interactions for the induction of inflammation
Boggio et al. Staphylococcus spp. skin colonization in anti-IL-4/IL-13 and anti-JAK-treated atopic dermatitis patients: proposal of a standardized protocol for research and clinical applications
Ettinger Probiotic therapy for heart failure: Investigating the potential anti-hypertrophic properties of probiotics
Molinaro Microbial modulation of metabolic diseases
Kim et al. Analysis of Liver Stiffness Measured by Transient Elastography in Autoimmune Hepatitis: 327
Harris Investigation of the IL-23 response to wheat gliadin, the primary etiologic agent in celiac disease
Overstreet Impact of antibiotic use, alternative therapies and inflammation on the intestinal microbiota

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20101208